Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Total Non-Current Liabilities (2020 - 2023)

Historic Total Non-Current Liabilities for Lexaria Bioscience (LEXX) over the last 5 years, with Q2 2023 value amounting to $142587.0.

  • Lexaria Bioscience's Total Non-Current Liabilities rose 67750.7% to $142587.0 in Q2 2023 from the same period last year, while for May 2023 it was $142587.0, marking a year-over-year increase of 67750.7%. This contributed to the annual value of $7401.0 for FY2022, which is 8519.47% down from last year.
  • According to the latest figures from Q2 2023, Lexaria Bioscience's Total Non-Current Liabilities is $142587.0, which was up 67750.7% from $7401.0 recorded in Q3 2022.
  • Lexaria Bioscience's 5-year Total Non-Current Liabilities high stood at $142587.0 for Q2 2023, and its period low was $7401.0 during Q3 2022.
  • For the 4-year period, Lexaria Bioscience's Total Non-Current Liabilities averaged around $61544.1, with its median value being $49989.0 (2021).
  • As far as peak fluctuations go, Lexaria Bioscience's Total Non-Current Liabilities crashed by 8519.47% in 2022, and later skyrocketed by 67750.7% in 2023.
  • Quarter analysis of 4 years shows Lexaria Bioscience's Total Non-Current Liabilities stood at $110821.0 in 2020, then crashed by 64.24% to $39629.0 in 2021, then tumbled by 81.32% to $7401.0 in 2022, then skyrocketed by 1826.59% to $142587.0 in 2023.
  • Its Total Non-Current Liabilities was $142587.0 in Q2 2023, compared to $7401.0 in Q3 2022 and $18339.0 in Q2 2022.